SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its recent earnings report, where the company exceeded revenue and EPS expectations, yet the stock experienced a notable after-hours decline. This unexpected dip, despite positive top and bottom-line results, has fueled community discussions ranging from claims of market manipulation to strong conviction among long-term investors buying the dip. Investors are actively debating the implications of the company's guidance, including its Q1 EPS forecast and projected doubling of ad revenue, alongside ongoing discussions about the strategic acquisition of Warner Bros. Discovery assets.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community discussion surges following CEO Ryan Cohen's significant additional share purchases, fueling speculation that the stock's bottom is in and a new 'meme season' could be on the horizon. Investors are actively debating a potential short squeeze and eagerly awaiting any communication from "Roaring Kitty," while noting the stock's notable resilience amidst broader market weakness.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending following compelling Phase 1 clinical trial data for its oral drug soquelitinib in atopic dermatitis, which demonstrated strong efficacy and a favorable safety profile, driving the stock to significant gains. Community discussion highlights both excitement for its potential as a best-in-class treatment for a large market and concerns surrounding a recently announced stock offering, with opinions split on whether it's a strategic funding move or a precursor to dilution. Investors are keenly watching the long-term implications of this early-stage therapeutic and its market validation.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as the market reacts to escalating geopolitical tensions stemming from President Trump's aggressive rhetoric regarding Greenland and proposed tariffs on European allies. Community discussions reflect widespread anxiety over potential economic instability and a significant market sell-off, with many anticipating continued downside amid concerns about international relations and a carry trade unwind.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant attention due to a highly positive FDA update for its ANKTIVA bladder cancer treatment, as the agency will not require new clinical trials for its resubmission, greatly de-risking the approval pathway. This development, combined with high short interest and massive trading volume, is driving strong community conviction around a potential short squeeze and the therapy's broader "cure for cancer" implications across multiple indications, even as the stock demonstrates notable resilience in a challenging market.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as renewed trade war concerns escalate following President Trump's rhetoric on Greenland and potential tariffs, fueling market uncertainty. Community sentiment is sharply divided between investors buying the dip and anticipating a swift rebound, and those bracing for a deeper correction. This geopolitical tension is broadly impacting sentiment around tech and AI-linked stocks, which are sensitive to risk-off moves.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding Ltd. (TWG) is trending due to its announced acquisition of a $125 million wine authentication and trading business, aimed at diversifying its luxury product portfolio beyond caviar. This news initially propelled the stock with massive percentage gains, but the community is now sharply divided, with many expressing frustration over a significant price drop, attributing it to substantial share dilution from the acquisition and a recent public offering. Investors are actively debating whether it's a "pump and dump" or if further upside remains given its volatile, low-float nature.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid news of new contracts with the U.S. Army for AI-driven logistics and the Department of Health and Human Services to establish a unified national health-data platform. This recent federal traction, combined with a deepened Microsoft partnership and high short interest, is driving intense debate between those anticipating a major turnaround and skeptics pointing to persistent revenue challenges and insider selling.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

Interactive Brokers is trending following a robust Q4 earnings report that highlighted aggressive growth in customer accounts and trading volumes across various asset classes. The community is also buzzing about its recent inclusion in the S&P 500 and the strategic move to enable 24/7 stablecoin account funding, positioning the company as a strong competitor in the evolving brokerage landscape despite some valuation debates.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing an extraordinary rally, driven by multiple analyst upgrades and the ongoing "memory and storage supercycle" fueled by strong AI-driven demand and tight supply conditions. This has sparked intense debate, with bulls pointing to its market-leading strength even amid broader tech weakness, while bears highlight extreme overvaluation and anticipate a significant correction, especially as earnings approach.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8%

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling...

<ul class="summary-bullets"><li>FDA is slated to decide on Disc Medicine's Bitopertin by February.&nbsp;</li><li>Approval for Lilly’s obesity pill is expected by April 10.</li><li>The FDA has also stalled the review of Sanofi’s Tzield for late-stage type 1 diabetes by more than a month over adverse event reports, Reuters said.</li></ul>Shares of Disc Medicine (IRON) fell 7% on Thursday after the U.S. Food and Drug Administration (FDA) reportedly delayed review of its drug Bitopertin despite choosing it for fast track review under a new voucher program.Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/us-fda-delays-two-drug-reviews-new-voucher-program-after-safety-efficacy-2026-01-15/">reported</a> on Thursday, citing internal documents, that the FDA delayed the review of the company’s experimental drug for treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns. EPP is a rare, inherited metabolic disorder causing extreme sensitivity to sunlight and artificial light, leading to immediate, painful skin reactions like burning, redness, and swelling.The reviewers pushed the drug’s potential approval by two weeks to Feb. 10 as they examine whether it has abuse risks. The agency also has concerns if pain-free time in the sun is a statistically solid measure of efficacy or if other data can justify approval, the report said.Disc Medicine’s Bitopertin is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program announced in June 2025. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.<h2 class="st-heading-2">Sanofi Faces Longer Delay</h2>The FDA has also stalled the review of Sanofi’s (SNY) Tzield for late-stage type 1 diabetes by more than a month over adverse event reports, Reuters said.The agency is considering the death of a patient while taking the drug and also evaluating two reports related to seizure and blood clotting. The agency was initially slated to decide on the application by Nov. 21.<h2 class="st-heading-2">Lilly’s Weight-Loss Drug Approval Now Slated For Q2</h2>Other drugs to face delays beyond the original target date include Boehringer Ingelheim's zongertinib for lung cancer and Eli Lilly’s (LLY) weight-loss pill. While zongertinib approval is now expected in mid-February, approval for Lilly’s obesity pill is expected by April 10, later than its initial first quarter (Q1) estimate, Reuters said.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> traded 4% lower at the time of writing while <a href="https://stocktwits.com/symbol/SNY">SNY shares</a> fell 1%.According to Reuters, at least seven drugs selected for priority review have started the approval process. While most of the reviews for the drugs selected for the program are slated to start this year, others are scheduled for 2027 and 2028.Only one antibiotic drug has been approved under the program as of date called Augmentin XR.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON and SNY stocks trended in the ‘Neutral’ territory at the time of writing. Retail sentiment around LLY, however, rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours.A Stocktwits user dismissed the delay report as a “short term hiccup.”<stembedurl>https://www.stocktwits.com/wwmeinc/message/641906137</stembedurl>Another opined that the selloff in IRON shares is a buying opportunity.<stembedurl>https://www.stocktwits.com/StockBraker/message/641896960</stembedurl><a href="https://stocktwits.com/symbol/IRON">IRON stock</a> has gained 18% over the past 12 months. &nbsp;&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-contemplating-deal-with-chinese-rival-byd-as-it-seeks-to-scale-hybrids-report/cmU1pwgR4JJ">Ford Contemplating Deal With Chinese Rival BYD As It Seeks To Scale Hybrids: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Disc Medicine logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers

Reuters reported on Thursday that the FDA delayed the review of Disc Medicine’s experimental drug for the treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns.

Equity

Reuters reported on Thursday that the FDA delayed the review of Disc Medicine’s experimental drug for the treatment of Erythropoietic Protoporphyria (EPP) after its scientists flagged safety and efficacy concerns.


Disc Medicine (NASDAQ:IRON) Shares Gap Down - Should You Sell?

Disc Medicine (NASDAQ:IRON) Shares Gap Down - What's Next...

Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 6,500 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 6,500 shares of Disc Medicine stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an...

Disc Medicine (NASDAQ:IRON) Insider Sells $511,485.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider Rahul Khara sold 6,500 shares of the company's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price...

Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirteen brokerages that are presently covering the company, Marketbeat...

<ul class="summary-bullets"><li>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule.&nbsp;</li><li>Wall Street analysts dismissed the media report hinting at approval delays and termed the share drop as overblown.&nbsp;</li><li>Disc Medicine is hopeful for an approval of the drug by the end of January 2026.</li></ul>Shares of Disc Medicine (<a href="https://stocktwits.com/symbol/IRON">IRON</a>) plunged 12% on Friday after a report flagged concerns pertaining to the U.S. Food and Drug Administration’s speedy approval of the company’s blood disorder drug Bitopertin.Disk Medicine’s Biopertin for the treatment of Erythropoietic Protoporphyria (EPP) is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program. The Commissioner's National Priority Voucher program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.However, Stat News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/12/19/fda-voucher-program-political-interference/">reported</a> on Friday, citing government officials, that high-level FDA officials have been involved in every part of the new program involving the vouchers. The political pressure is creating “uncomfortable situations” for career scientists at the FDA, the report said.The report dragged down investor sentiment and hopes for an expedited approval of Bitopertin as the report also noted that FDA senior official Vinay Prasad raised doubts about the drug’s effectiveness.<h2 class="st-heading-2">Wall Street Dismisses Concerns</h2>Jefferies analyst Roger Song, however, termed the share drop a “stock overreaction”. Song said that while the priority voucher program's timeline may be under pressure with increasing demand, the firm remains confident on Bitopertin's approval in EPP under the program, based on robust efficacy and safety data and to-date review experience.TD Cowen also maintained its ‘Buy’ rating on the shares and said the firm believes skepticism on the program’s path is overblown. Disc's management remains confident, it noted, and added that the firm's confidence in accelerated approval remains high.BMO Capital said that it had discussions with Disc Medicine’s management which highlighted a lack of interactions with senior official Prasad but robust active dialogue with the FDA. While Prasad may have speculated efficacy concerns related to Bitopertin, these have not been communicated to Disc, and no clear concerning questions around efficacy have been raised, BMO added. Some procedural questions have been asked by FDA in trying to understand the Bitopertin data package and how it may translate to clinical benefit, it said. The firm has an ‘Outperform’ rating on the shares with a price target of $120.<h2 class="st-heading-2">Management Takeaway</h2>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule and expressed hopes for potential launch by the end of January 2026, consistent with the 1-2 month timeline for drugs which receive the priority voucher.“Our commercialization efforts have been accelerated significantly and we are well on our way to launch readiness,” the company said.The company submitted its application for approval in patients aged 12 years and older with EPP on September 29. Erythropoietic Protoporphyria (EPP) is a rare, inherited metabolic disorder causing extreme sensitivity to sunlight (phototoxicity), leading to immediate, painful skin reactions like burning, tingling, redness, and swelling, due to the buildup of protoporphyrin in red blood cells from an enzyme deficiency.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON stayed within the ‘bearish’ territory while message volume rose from ‘low’ to ‘high’ levels.IRON stock has gained about 26% this year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-intel-shares-jump-after-us-antitrust-agencies-clear-5-billion-deal/cLe0d1gREtc">Nvidia, Intel Shares Jump After US Antitrust Agencies Clear $5B Deal That Deepens Their Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’

Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program. 

Disc Medicine Enters Oversold Territory (IRON)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Disc Medicine (NASDAQ:IRON) Shares Down 9% After Insider Selling

Disc Medicine (NASDAQ:IRON) Shares Down 9% Following Insider Selling...

Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 754 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Kevin Bitterman sold 754 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold...

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.75	--	--	N/A
Q3 '25	-$1.44	-$1.77	-22.74%	MISSED
Q2 '25	-$1.13	-$1.58	-40.05%	MISSED
Q1 '25	-$1.11	-$1.02	7.87%	BEAT
Q4 '24	-$1.11	-$0.95	14.30%	BEAT

IRON
Disc Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest IRON News

IRONDisc Medicine Inc